3.06
-0.15 (-4.53%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Armata Pharmaceuticals, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -2.5 |
| AI Insight | NA |
| 平均 | 0.17 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 69.55% |
| 机构持股比例 | 2.13% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Dauntless Investment Group, Llc | 30 Jun 2026 | 203,891 |
| Edgewood Management Llc | 30 Jun 2026 | 80,000 |
| Grey Ledge Advisors, Llc | 30 Jun 2026 | 50,000 |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合